Xaluritamig (AMG 509): Promising Updates on a STEAP1-Targeted Therapy for Advanced Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxPhase 3 Clinical Trial for Xaluritamig (AMG 509) in Advanced Prostate Cancer Set to Open for Recruitment Soon
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxMetformin Shows Promise in Reducing Side Effects of Hormone Therapy in Advanced Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxTruqap Shows Promise in Treating a Subtype of Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxFDA Accepts Darolutamide Plus ADT sNDA for mHSPC Treatment
/0 Comments/in Clinical Trial, FDA approvals, Metastatic, Phase 3/by MaxPhase III Trial for Metastatic Castration-Resistant Prostate Cancer of an EZH2 inhibitor
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxAMPLITUDE phase 3 Study for Metastatic Castration-Sensitive Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxPromising Results for 177Lu-PSMA-I&T in Prostate Cancer Treatment
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxPhase 3 trial: 177Lu-DOTA-rosopatamab (TLX591) for patients with PSMA expressing metastatic castration-resistant prostate cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxTags
abiraterone acetate ADT alphafold androgen deprivation therapy antibody-drug conjugate apalutamide ATM bispecific antibody bone metastases BRCA cancer immunotherapy cancer treatment castration-resistant prostate cancer chemotherapy clinical trial clinical trials crispr darolutamide diet docetaxel drug discovery drug repurposing drug resistance enzalutamide hormone therapy immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer metformin mHSPC neuroendocrine prostate cancer oncology oncolytic virus personalized medicine prostate cancer PSMA radioligand therapy radiopharmaceuticals real-world data STAMPEDE trial survival outcomes T-cell therapy theranostics treatment resistance
Latest Posts
- VIR-5500: A Promising T-Cell Engager for Advanced Prostate Cancer January 14, 2025
- Preclinical: NRM-823, a Breakthrough T-Cell Engager Targeting Advanced Prostate Cancer January 14, 2025
- RPT04402 Reactivating PP2A: A Different Approach in Advanced Prostate Cancer Therapy January 14, 2025
- Phase 1b Promising Results: ORIC-944, a PRC2 Inhibitor for Advanced Prostate Cancer January 14, 2025